Get started
Work

Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032

Year: 2015
Type: article
Abstract: Meeting abstracts Treatment options for SCLC after failing platinum-based (PLT) chemotherapy (CT) are limited. Combined blockade of programmed death-1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) immune checkpoint pathways has anti-tumor activity with a manageable safety profile. Nivolumab
DOI: 10.1186/2051-1426-3-s2-p376
Authors: Matthew Taylor, Scott Antonia, Johanna Bendell, Emiliano Calvo, Dirk Jäger, Filippo de Braud, Patrick A Ott, M Catherine Pietanza, Leora Horn, Dung T Le, Michael A Morse, José A López-Martin, Paolo A Ascierto, Olaf Christensen, Jason S Simon, Chen-Sheng Lin, Joseph Paul Eder
Institutions: Oregon Health & Science University, Moffitt Cancer Center, Sarah Cannon Research Institute, Tennessee Oncology, University Hospital Heidelberg, Fondazione IRCCS Istituto Nazionale dei Tumori, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Duke Medical Center, Hospital Universitario 12 De Octubre, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Bristol-Myers Squibb (United States), Yale Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,490
OpenAlex ID: W2187132200
FWCI: 1.304
Cites:
Cited by: 18
Related to: 10